New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis

Hyun Young Woo and Jeong Heo
Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Korea

Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoembolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival. (Clin Mol Hepatol 2015;21:115-121)

Keywords: Management; Hepatocellular carcinoma; Portal vein thrombosis

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer, and the third most common cause of cancer-related death worldwide.1 It is responsible for over 600,000 deaths annually.2 When patients with HCC have been detected early, curative treatment such as resection and percutaneous ablation are feasible. However, approximately 10-40% patients with HCC have portal vein thrombosis (PVT) at the time of diagnosis.3,4 Overall survival have been reported to be much shorter in patients with PVT, compared to patients without PVT, because these patients have more chances to have metastatic disease at diagnosis and fewer therapeutic options. Reported overall survival ranged from 2-4 months in patients with PVT treated with supportive care, compared to 10-24 months in HCC patients without PVT.3,5 If thrombus involved the main portal vein, the prognosis would be much worse than in case of thrombus involving a branch portal vein.6

For decisions regarding initial treatments, the Barcelona Clinic Liver Cancer (BCLC) staging system from Western guidelines is frequently applied.7,8 In this system, management options for HCC with PVT are more limited than for HCC without PVT. As three-quarters of HCC cases occur in East Asia, the experiences and data in this area should have been substantially accumulated, so this article aim to review the current status and future prospect of the management of HCC with PVT (Table 1).

SURGICAL MANAGEMENT

Liver resection produces the best prognosis when it involves
only one or two small tumors. Surgical resection for PVT generally resulted in poorer outcomes. Surgical resection for HCC with PVT is more frequently employed across Asia. Overall median survival for patients with portal vein invasion ranged from 9 to 33 months according to the degree of portal vein invasion. In a study of 438 PVT patients who underwent resection for PVT, overall survival was 18.8 months with branch portal invasion and 10.1 months with main portal invasion. In general, outcomes of surgical resection for tumors involving the main portal vein remain relatively poor (median survival, 9-10 months; and 3-year survival rates, 0-6%). The main problem of liver resection is that it is often technically infeasible in patients with PVT. The operative mortality rates is 0-6%.

**TRANSARTERIAL CHEMOEMBOLIZATION**

Transarterial chemoembolization (TACE) is widely used as a first-line treatment for unresectable HCC and is recommended for patients with BCLC stage B, multinodular asymptomatic tumors, and without vascular invasion or extrahepatic spread. A study of the survival benefits of TACE found that the survival time was longer for intermediate-stage patients (BCLC stage B) treated with TACE (median survival, 19–20 months) than for untreated intermediate-stage controls (median survival, 16 months). Indications for TACE are the absence of vascular invasion and extrahepatic spread, a preserved underlying liver function (mostly Child-Pugh class A or B7 without ascites), and asymptomatic multinodular tumors. Since performing TACE on patients with portal vein invasion or advanced liver failure causes serious complications due to ischemic events in the liver, chemoembolization is not recommended for the patients with decompensated liver cirrhosis, advanced liver dysfunction (Child-Pugh class C), macroscopic invasion, and extrahepatic spread.

However, in some patients with compensated liver function, TACE can be performed safely with superselective method and is associated with improved overall survival compared to supportive care. In recent two large meta-analysis, TACE was favored over supportive care for HCC with main as well as branch portal vein tumor thrombus. Overall survival among PVT patients treated with TACE in these studies ranged from 7.0 to 10.2 months. Notably, median survival after TACE prolonged as much as 22-30 months when a tumor is nodular and restricted to 1 lobe or 1-2 segments and hepatic function is preserved, even in the presence of main portal vein tumor thrombosis.

Therefore, TACE is considered to be a one of therapeutic option for selected patients with PVT, if their underlying liver function is favorable and the procedure is technically possible. However, reported overall survival of 7.4 to 10.2 months is not significantly better than systemic sorafenib.

**EXTERNAL RADIATION THERAPY**

External radiation therapy for liver lesions has not been broadly performed in patients with compromised underlying liver function due to risk of radiation-induced liver disease. However, with advanced of newer techniques, in the form of stereotactic body radiation therapy, high doses of radiation can be delivered very selectively, with relative sparing of non-tumorous liver parenchyma.

The effect of external radiation therapy in HCC with PVT has not been well studied and the use of external radiation therapy for HCC is not yet regarded as standard treatment, but remains an area of active investigation. The median survival was shown to be 9.2 months in a large multicenter study in Korea of 994 HCC patients with portal vein tumor thrombosis. Studies from Japan

---

**Table 1. Summary of management for hepatocellular carcinoma with portal vein thrombosis**

| Survival data (months) | Adverse events |
|------------------------|---------------|
|                        | Overall survival | Main PVTT | Branch PVTT | |
| Supportive care        | 2-4            |           |            |     |
| Surgical resection     | 9-33           | 9-10      | 9-10       | Operative mortality; 0-6% |
| TACE                   | 7-10           |           |            | Liver failure, postembolization syndrome |
| External radiation therapy | 9.2          |           |            | Radiation induced liver disease |
| HAIC                   | 6-7            |           |            | |
| Radioembolization      | 10             | 4.5       | 16         | Fatigue, hyperbilirubinemia, GI ulceration |
| Sorafenib              | 6-8            |           |            | Skin reaction, diarrhea, fatigue |

HAIC, hepatic artery infusion chemotherapy; PVTT, portal vein tumor thrombosis; TACE, transarterial chemoembolization; GI, gastrointestinal.
and China also reported that overall survival in patients receiving radiotherapy was 10.9 months and 12.3 months and it is significantly better than in patients receiving sorafenib (4.8 months, \(P=0.025\)) or undergoing surgery (10.3 months, \(P=0.029\)). In other studies, when external radiation therapy is combined with other modalities such as sorafenib or TACE, overall survival was reported to be 10 months or more. Although these data of radiotherapy in advanced HCC, radiotherapy has not been incorporated into the international guidelines for HCC because of lack of prospective randomized trial. Therefore, there are urgent needs for well-designed randomized controlled studies.

RADIOEMBOLIZATION

Radioembolization involves injection of \(^{131}\)I-labeled lipiodol or glass microspheres containing an isotope into the hepatic artery. The most widely used isotope is yttrium-90 (\(^{90}\)Y), which emits pure, high-energy \(\beta\) particles, has a half-life of 2.67 days, and an average penetration power of 2.5 mm (maximum, 11 mm). Resin or glass microspheres with a diameter of 35 \(\mu\)m are used to transport the \(^{90}\)Y. The injected microspheres minimize the thrombotic effect in the artery and are distributed in high concentrations in hypervascular HCC tumors, displaying a radiation-induced antitumor effect. Nuclear medical examination using technetium-99m microaggregated albumin is required in advance of the radioembolization procedure to determine the treatment locations, the required dose of radiation, and measure the risk and degree of exposure to organs other than the target (i.e., the liver).

\(^{90}\)Y has been mainly studied as a locoregional therapy for unresectable HCC that is not amenable to TACE because of diffuse or multifocal disease, or as an alternative to TACE. The efficacy of \(^{90}\)Y in patients with HCC who had PVT could be found in subgroup analysis from the three largest series of HCC patients treated with \(^{90}\)Y. In these series, patients who had PVT demonstrated remarkably similar overall survival times ranging from 10.0 to 10.4 months among all patients with PVT. One of these studies reported that overall survival was 16.6 months among Child-Pugh A cirrhosis with branch PVT and it was decreased to 4.5 months among Child-B cirrhosis with main PVT. Smaller series of patients with PVT treated with \(^{90}\)Y have reported overall survival ranging from 7.2 to 13 months. In another small nonrandomized study, among patients with major vascular invasion, the \(^{90}\)Y group showed an overall survival of 12.0 months, compared to 8.0 months in the TACE group.

In addition, in term of safety, patients receiving radioembolization needed less hospitalization and fewer treatments. Fewer treatment sessions should improve quality of life and reduce the possibility of liver derangement; therefore, in these respects, radioembolization is considered better than conventional TACE and another option for patients with PVT.

CYTOTOXIC CHEMOTHERAPY

Cytotoxic chemotherapy has known to be not effective through most clinical trials to date. It is because delayed metabolism of chemotherapeutic agents in the presence of liver cirrhosis may enhance their toxicity and HCC is relatively chemo-resistant to most cytotoxic anticancer drugs. Instead, Hepatic arterial infusion chemotherapy (HAIC) has been investigated for treatment of advanced HCC with portal vein tumor thrombosis in Asian countries. In HAIC, chemotherapeutic agent is infused into the hepatic artery via an implanted catheter, which reduces systemic side-effects by first pass effects and maximizes drug delivery to the tumor. Furthermore, HAIC does not use embolic material, therefore the presence of tumor thrombus may not aggravate ischemic injuries after TACE. In clinical data on HAIC, low dose or high dose of cisplatin and 5-fluorouracil was mainly used as chemotherapeutic agents and the effect of HAIC was compared to systemic chemotherapy or supportive care or sorafenib. In those studies, HAIC showed survival benefit compared to other treatments modalities (median survival 6-7 months versus 5.5, 4 and 2 months in sorafenib, systemic chemotherapy and supportive care, respectively). Although there are no well-designed prospective studies to demonstrate these results, HAIC can be an alternative therapy for patients with portal vein tumor thrombosis, especially in case that patients with advanced HCC do not respond or are intolerant to standard therapy.

MOLECULAR TARGET THERAPY

Sorafenib is the multi-tyrosine-kinase inhibitor that targets vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, and the Raf-1 and c-kit receptors. Sorafenib was the first ever molecularly targeted agent confirmed for the treatment of HCC. In a phase III, multicenter, randomized controlled trial (RCT) conducted on a Western population, the median survival period of patients with progressive HCC with he-
patent portal invasion and extrahepatic spread who were treated with sorafenib was 10.7 months, which was significantly higher than the median survival period (7.9 months) of the control group, who were treated with palliative medicine alone \( (P=0.00058) \). In this study, sorafenib also prolonged the time to tumor progression \( (TTP; 5.5\) months and 2.8 months for the sorafenib-treated and control groups, respectively). In a subgroup analysis, 45 patients with macroscopic vascular invasion, presumably largely consisting of PVT, had an overall survival of 8.1 months in the sorafenib group, compared to 4.9 in the control group. The respective times to progression were 4.1 and 2.7 months. In a phase III, RCT conducted in Pacific Asia by the Asian Pacific Association for the Study of the Liver, the median survival period of patients with progressive HCC who were treated with sorafenib was 6.5 months, which was again significantly higher than that of the control group \( (4.2\) months; hazard ratio, 0.68; 95% confidence interval, 0.50–0.93; \( P=0.014) \). In subgroup analyses, 46 sorafenib was found to have modestly prolonged survival in patients with macroscopic vascular invasion and/or extrahepatic spread of tumor \( (5.6\) months vs 4.1 months). TTP was likewise somewhat prolonged \( (2.7\) months vs. 1.2 months). The most frequent adverse reactions to sorafenib are hand-foot skin reaction, diarrhea, and fatigue, which occur during the treatment in 40% of patients and it may necessitate dose reduction or discontinuation in a minority of patients.

Sorafenib is considered as a standard treatment for patients with unresectable HCC whose liver function was well-compensated \( (\text{Child-Pugh A})\). Several studies reported that a portion of Child-Pugh B also may show survival benefit from sorafenib treatment. 47, 48

The main problem of sorafenib is that, although a select group of patients showed excellent response to sorafenib, 49, 50 the majority of patients with PVT have shown just modest response and survival. Therefore, there are continued efforts to improve the efficacy of sorafenib. First, combination of sorafenib with locoregional therapies remains an area of active investigation. Second, newer agents were evaluated in clinical trials.

**COMBINATION THERAPY**

**Sorafenib combined with TACE**

In studies comparing TACE plus sorafenib and sorafenib alone, overall survival and time to progression \( (TTP) \) was significantly longer in combination group than sorafenib alone group \( (\text{median survival, 8.9 and 5.9 months, respectively}; \ P=0.009) \) \( (TTP, 2.5\) and 2.1 months, respectively; \( P=0.008) \). Another study also showed that the efficacy of TACE plus sorafenib is more superior than TACE alone in advanced stage HCC patients in terms of overall survival and TTP \( (\text{overall survival, 7.0 and 4.9 months, respectively}; \ P=0.003) \) \( (TTP, 2.6\) and 1.9 mo, respectively; \( P=0.001) \). A phase II study which combined drug eluting bead TACE with sorafenib showed objective response rate of 58% and disease control rate of 100% in advanced HCC patients. These data showed that the combination is a promising HCC treatment strategy, but its benefits compared with monotherapy needs to be confirmed in a prospective randomized trial.

**Sorafenib combined with radiotherapy**

The combination treatment using sorafenib and radiotherapy are thought to be synergistic because in vitro and in vivo experiment showed sorafenib enhance the radiosensitivity of human HCC cell lines by inhibiting radiation-induced activation of vascular endothelial growth factor receptors \( (\text{VEGFRs})\), a downstream kinase \( (\text{extracellular signal regulated kinase})\), and nuclear factor-\( \kappa \)B and by increasing radiation-induced apoptosis. In a multicenter phase II study in which sorafenib was administered after radioembolization, the median overall survival time was 8.6 months in patients with advanced stage HCC. \( 51 \) Considering the median survival of phase III Asian-Pacific trial data of sorafenib was 6.5 months in advanced HCC, the data of radioembolization plus sorafenib combination therapy seems to be favorable. \( 46 \) About data of sorafenib plus external beam radiation, a phase II study of sorafenib therapy plus external beam radiation reported an initial complete or partial response rate of 55% and a 2-year overall survival rate of 32% in 40 Taiwanese patients with advanced HCC. These results are promising but further research would be needed.

**Emerging therapy**

Besides sorafenib, several newer molecular target agents are investigated but so far none of these drug such as sunitinib, brivanib, linfaniib, or the combination of sorafenib and erlotinib have demonstrated efficacy in phase III trials, either in the setting of progression on sorafenib or as primary therapy. \( 52 \) However, recent two trials showed encouraging results in subgroup analysis. In a phase 2 study about tivantinib, MET inhibitor, progression free survival was significantly improved compared to placebo.
and patients with high MET expression had showed substantial benefit from tivantinib in terms of median overall survival (7.2 months vs. 3.8 months, \(P=0.01\)).\(^5\) Furthermore, in a phase 3 trial of the vascular endothelial growth factor receptor-2 antibody, ramucirumab, median survival was significantly improved in patients with baseline alpha-fetoprotein more than 400 ng/mL. The efficacy of these agents will be investigated in further study.

Moreover, immunotherapeutic agent such as checkpoint inhibitor (CTLA-4 antibody, programmed cell death receptor-1 blocking antibody) and oncolytic viruses are another promising agent because HCC showed immunologic response spontaneously or to adoptive immunotherapy. Phase I trial (NCT01853618) for tremelimumab (CTLA-4 antibody) and phase I/2 trial (NCT01658878) for nivolumab (programmed cell death receptor-1 blocking antibody) are currently undertaken. Oncolytic viruses are also promising agent because these viruses preferentially replicated in cancer cells as well as final kill the cancer cells.\(^6\) In HCC, several oncolytic viruses have been investigated and JX-594 is currently leading agent among these viruses.\(^6\) JX-594 is a genetically engineered vaccinia virus and its action mechanism is to induce virus replication-dependent lysis of tumor cells as well as to induce tumor specific immunity. In phase 2 clinical trial of JX-594, high dose of JX-594 showed overall survival about 14.1 months in advanced HCC.\(^6\) Further study of this virus are under investigation in advanced HCC.

**CONCLUSIONS**

Despite recent progress in the treatments for HCC, treatment for patients with PVT remain still as challenging area. Current clinical guideline recommend sorafenib only. However, besides sorafenib, various therapies including surgery, TACE, external radiation therapy, HAIC and radioembolization may be management options in selected patients and the usefulness of combination treatment need to be verified. Newer therapeutic options such as such as immunotherapeutic agent and oncolytic virus are under investigation.

**Acknowledgements**

This work was supported for 2 years by a Pusan National University Research Grant.

**Conflicts of Interest**

The authors have no conflicts to disclose.

**REFERENCES**

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-458.
3. Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther 2006;24:573-583.
4. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-67.
5. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103-109.
6. Lau WY, Sangro B, Chen PI, Cheng SQ, Chow P, Lee RC, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 2013;84:311-318.
7. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-1022.
9. Omata M, Lesmana L, Tateishi R, Chen P-J, Lin S-M, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:334-364.
10. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, et al. Effects of Location and Extension of Portal Vein Tumor Thrombus on Long-Term Outcomes of Surgical Treatment for Hepatocellular Carcinoma. Annals of Surgical Oncology 2006;13:940-946.
11. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology 2000;32:1224-1229.
12. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
13. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796-802.
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
15. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of hepatology 2008;48:S20-S37.
16. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RTP, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
17. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:5179-5188.
18. Pinter M, Huckle F, Grazierdel I, Vogel W, Maieron A, Koningberg R, et al. Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology 2012;263:590-599.
19. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology 2011;258:627-634.
20. Luo J, Guo R-P, Lai EH, Zhang Y-J, Lau W, Chen M-S, et al. Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Ann Surg Oncol 2011;18:413-420.
21. Leng Jj, Xu YZ, Dong JH. Efficacy of chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg 2014 Aug 3. [Epub ahead of print]
22. Xue TC, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterology 2013;13:60.
23. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol 1995;165:315-321.
24. Dawson LA, Ten Haken RK. Partial Volume Tolerance of the Liver to Radiation. Seminars in Radiation Oncology 2005;15:279-283.
25. Jiang W, Zeng ZC. Is It Time to Adopt External Beam Radiotherapy in the NCCN Guidelines as a Therapeutic Strategy for Intermediate/Advanced Hepatocellular Carcinoma? Oncology 2013;84(suppl 1):69-74.
26. Yu Jl, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, et al. Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. Cancer Res Treat 2014;46:348-357.
27. Nakazawa T, Hidaka H, Shibuya A, Okuwa K, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol 2014;14:84.
28. Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg 2013;37:1362-1370.
29. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009;29:65-71.
30. Park MS, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol 2013;71:165-173.
31. Raoul J, Guyader D, Bretagne J, Heauott J, Duvaufrière R, Bourquet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled–iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-1161.
32. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
33. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.
34. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival. Hepatology 2010;52:1741-1749.
35. Sangro B, Carpanese L, Cianni R, Golferi R, Gasparini D, Ezzidin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-878.
36. Salem R, Lewandowski R, Roberts C, Goin J, Thurstom K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345.
37. Yeo W, Mok TS, Zee R, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
38. Qin S, Bai Y, Ye S, Fan J, Lim H, Cho J, et al. Randomized, multi-center, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2010;31:3501-3508.
39. Lai CL WP, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no anti-tumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
40. Inaba Y, Arai Y, Yamaura H, Sato Y, Najima M, Aramaki T, et al. Phase III study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol 2011;34:58-62.
41. Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2012;8:164-171.
42. Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2009;32:127-133.
43. Hiramine Y, Uto H, Inamura Y, Tabu K, Baba Y, Hiwaki T, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med 2011;2:433-441.
44. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
45. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-829.
46. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
47. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012;48:1452-1456.
48. Ozene V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouatour M, et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010;22:1106-1110.
49. Barbier L MF, Le Guellec S, Pariente A, Otal P, Sac B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol 2011;2011:791013.
50. Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver 2013;7:696-703.
51. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013;269:603-611.
52. Hu H, Duan Z, Long X, Hertzman Y, Shi H, Liu S, et al. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One 2014;9:e96620.
53. Pawlik TM RD, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-3967.
54. Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013;329:109-117.
55. Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, et al. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One 2014;9:e90909.
56. Chen SW LL, Kuo YC, Liang JA, Kuo CC, Chiu JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-1047.
57. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014;20:2072-2079.
58. Eathiraj S PR, Volkova E, Hirsch M, France DS, Ashwell MA, Chan TC. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011;286:20666-20676.
59. Melcher A PK, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011;19:1008-1016.
60. Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 2011;19:1170-1179.
61. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-336.